Warp Sciences raises $215 million for robotic drug-discovery labs
The AMW Read
A well-funded entrant targets drug discovery's physical experimentation bottleneck, with former OpenAI science lead Kevin Weil extending frontier-lab talent into laboratory robotics; operating economics remain unproven.
Warp Sciences raises $215 million for robotic drug-discovery labs
Warp Sciences, launched by former OpenAI science lead Kevin Weil, has raised $215 million at an $865 million valuation, according to TechCrunch's account of Weil's announcement on X. Lightspeed led the round, with IVP, Premji Invest, and Lux Capital participating. The startup trains robots to synthesize and test promising compounds identified by researchers. Human chemists wearing cameras and sensor gloves will demonstrate laboratory tasks, with the aim of enabling robots to work around the clock.
The company targets the physical experimentation bottleneck in AI-enabled drug discovery: identifying a promising molecule still leaves the work of making and testing it. Its approach connects healthcare AI with robotics trained through human demonstrations, making laboratory execution the central investment proposition. Weil also wants to reshore synthesis work that biotech companies have outsourced to Chinese contractors such as WuXi AppTec, positioning automation as a response to geopolitical supply-chain exposure. The launch brings a former frontier-lab executive into the effort to automate experimental science.
For builders and investors, the concrete diligence question is whether robotic execution can deliver reliable experiments at an attractive cost. Useful evidence would include synthesis throughput, repeatability, human intervention rates, and cost per tested compound. The report provides no operating results on those measures, so the funding establishes financial backing while leaving the laboratory economics unproven.
